Xaira Therapeutics, an AI-driven biotechnology startup that emerged earlier this year with a $1 billion funding round, continues to demonstrate its ambitions and staying power. Despite recent biotech industry turbulence, with some AI-focused biotech firms announcing layoffs and restructuring, Xaira has doubled down on growth. The firm is bolstering its leadership roster while announcing a…
Overcoming the biotech investment paradox
As COVID wreaked havoc on our markets, biotech appeared to be an outlier, not just weathering the storm but emerging stronger than ever with record investments and valuations. Then reality struck. Assets lingered in the early stages. Commercialized products underperformed. Valuations tumbled. Now, a new normal has arrived, presenting a biotech investment paradox to small…